智通财经APP讯，药捷安康-B(02617)发布公告，根据恒生指数有限公司于2026年2月13日公布的恒生指数系列季度检讨结果，本公司已获选并将纳入包括但不限于下述恒生指数系列成份股，自2026年3月9日起生效：
1.恒生综合大中型股指数;2.恒生大中型股(可投资)指数; 3.恒生综合中型股指数; 4.恒生港股通指数; 5.恒生港股通中小型股指数; 6.恒生大中型股等权重混合因子(QVLM)指数; 7.恒生大中型股低波幅全选指数; 8.恒生大中型股动量全选指数; 9.恒生大中型股质量全选指数; 10.恒生大中型股风险平价混合因子(QVLM)指数; 11. 恒生大中型股规模全选指数; 12. 恒生大中型股价值全选指数; 13. 恒生大中型股股息率全选指数; 14. 恒生港股通中国内地公司指数;及 15. 恒生沪深港通生物科技50指数。
同时，本公司已从恒生综合小型股指数中剔除，自2026年3月9日起生效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.